On January 17, 2025, Novo Nordisk announced that semaglutide 7.2 mg achieved a 20.7% weight loss in a study, outperforming both semaglutide 2.4 mg and placebo. The trial involved 1,407 adults with obesity, showcasing significant efficacy in weight management.